Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019032383) [1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/032383 International Application No.: PCT/US2018/045081
Publication Date: 14.02.2019 International Filing Date: 03.08.2018
IPC:
C07D 487/04 (2006.01) ,A61K 31/4985 (2006.01) ,A61P 3/10 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
Applicants:
ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, Indiana 46285, US
Inventors:
GENIN, Michael James; US
HOLLOWAY, William Glen; US
JESUDASON, Cynthia Darshini; US
SHI, Qing; US
Agent:
LENTZ, Nelsen L.; US
COMBS, Tonya L.; US
Priority Data:
62/543,42710.08.2017US
Title (EN) [1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES
(FR) DÉRIVÉS DE [1,2,4] TRIAZOLO UTILISÉS EN TANT QU'INHIBITEURS DE PDE1 POUR LE TRAITEMENT DU DIABÈTE
Abstract:
(EN) The present invention provides a compound of Formula I: wherein X is CH2CH2, CH2CH2CH2, OCH2, or CH2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH2CH2, then R is other than cyclopropyl; for use as a human PDE1 inhibitor.
(FR) La présente invention concerne un composé de formule I : dans laquelle X représente CH2CH2, CH2CH2CH2, OCH2, ou CH2O ; et R est l'éthyle, n-propyle, cyclopropyle ou cyclobutyle ; ou un sel pharmaceutiquement acceptable de celui-ci ; à condition que lorsque X représente CH2CH2, alors R est différent du cyclopropyle ; l'invention concerne également une utilisation du composé en tant qu'inhibiteur de PDE1 humain.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)